Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy

Related Experiment Video

Updated: May 14, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Y Xu1, L Diao, Y Chen

  • 1Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Breast Center, Peking University Cancer Hospital & Institute, Beijing, PR China.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|February 15, 2013
PubMed
Abstract

Insights

BRCA1 promoter methylation in triple-negative breast cancer predicts better survival with chemotherapy. Unmethylated BRCA1 in non-triple-negative breast cancer indicates poorer outcomes. This finding impacts treatment strategies for breast cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • BRCA1 gene promoter methylation inactivates BRCA1 function in many triple-negative breast cancers (TNBC).
  • Understanding BRCA1 methylation's impact on chemotherapy efficacy is crucial for TNBC and non-TNBC patient outcomes.

Purpose of the Study:

  • To investigate the association between BRCA1 promoter methylation status and the effectiveness of adjuvant chemotherapy.
  • To determine if BRCA1 methylation influences survival in triple-negative and non-triple-negative breast cancer patients receiving chemotherapy.

Main Methods:

  • BRCA1 promoter methylation was assessed in 1163 unselected breast cancer patients using methylation-specific PCR (MSP).
  • Survival outcomes (DFS and DSS) were analyzed in relation to BRCA1 methylation status in TNBC and non-TNBC subgroups treated with adjuvant chemotherapy.

Main Results:

  • In 167 TNBC patients receiving chemotherapy, BRCA1-methylated tumors showed significantly better 10-year DFS (78% vs. 55%) and DSS (85% vs. 69%) compared to unmethylated tumors.
  • BRCA1 methylation was an independent favorable predictor for DFS and DSS in TNBC patients (HR 0.45 and 0.43, respectively).
  • Conversely, in 675 non-TNBC patients receiving chemotherapy, BRCA1 methylation was an unfavorable predictor for DFS and DSS (HR 1.56 and 1.53, respectively).

Conclusions:

  • Triple-negative breast cancer patients with BRCA1-methylated tumors exhibit sensitivity to adjuvant chemotherapy, leading to favorable survival outcomes.
  • BRCA1 methylation status differentially impacts chemotherapy efficacy and survival based on breast cancer subtype (TNBC vs. non-TNBC).
  • This study highlights the prognostic and predictive value of BRCA1 methylation in guiding breast cancer treatment decisions.
Keywords:
BRCA1 methylationchemotherapytriple-negative breast cancer

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Methyl-binding DNA capture Sequencing for Patient Tissues08:40

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...